share_log

Insiders Own 31% of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares but Retail Investors Control 44% of the Company

Insiders Own 31% of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares but Retail Investors Control 44% of the Company

業內人士擁有瀋陽興奇藥業有限公司 31% 的股份, Ltd.(深交所代碼:300573)持有公司 44% 的股份,但散戶投資者控制着該公司 44% 的股份
Simply Wall St ·  2023/11/24 18:06

Key Insights

關鍵見解

  • Significant control over Shenyang Xingqi PharmaceuticalLtd by retail investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 14 investors have a majority stake in the company with 51% ownership
  • 31% of Shenyang Xingqi PharmaceuticalLtd is held by insiders
  • 散戶投資者對瀋陽興奇製藥有限公司的重大控制意味着公衆有更大的權力影響管理和治理相關決策
  • 共有14名投資者擁有該公司的多數股權,擁有51%的所有權
  • 瀋陽興奇藥業有限公司31%的股份由內部人士持有

A look at the shareholders of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are retail investors with 44% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

看看瀋陽興奇藥業有限公司的股東,Ltd.(深圳證券交易所代碼:300573)可以告訴我們哪個集團最強大。而佔有最大份額的群體是擁有44%所有權的散戶投資者。換句話說,該集團面臨着最大的上行潛力(或下行風險)。

Meanwhile, individual insiders make up 31% of the company's shareholders. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones.

同時,個人內部人士佔公司股東的31%。機構通常會持有大型公司的股票,我們預計內部人士將擁有相當一部分小型公司的股票。

Let's delve deeper into each type of owner of Shenyang Xingqi PharmaceuticalLtd, beginning with the chart below.

讓我們從下表開始,更深入地研究瀋陽興奇製藥有限公司的每種類型的所有者。

Check out our latest analysis for Shenyang Xingqi PharmaceuticalLtd

查看我們對瀋陽興奇藥業有限公司的最新分析

ownership-breakdown
SZSE:300573 Ownership Breakdown November 24th 2023
深交所:300573 所有權明細 2023 年 11 月 24 日

What Does The Institutional Ownership Tell Us About Shenyang Xingqi PharmaceuticalLtd?

機構所有權告訴我們關於瀋陽興奇藥業有限公司的什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

We can see that Shenyang Xingqi PharmaceuticalLtd does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Shenyang Xingqi PharmaceuticalLtd, (below). Of course, keep in mind that there are other factors to consider, too.

我們可以看到,瀋陽興奇製藥有限公司確實有機構投資者;他們持有公司很大一部分股票。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎行事,不要依賴機構投資者提供的假定驗證。有時候他們也會弄錯。如果兩個大型機構投資者試圖同時拋售一隻股票,股價大幅下跌的情況並不少見。因此,值得一看瀋陽興奇製藥有限公司過去的收益軌跡(見下圖)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
SZSE:300573 Earnings and Revenue Growth November 24th 2023
深交所:300573 收益和收入增長 2023年11月24日

We note that hedge funds don't have a meaningful investment in Shenyang Xingqi PharmaceuticalLtd. Jidong Liu is currently the largest shareholder, with 29% of shares outstanding. With 4.8% and 3.4% of the shares outstanding respectively, National Council for Social Security Fund and Fullgoal Fund Management Co. Ltd. are the second and third largest shareholders. In addition, we found that E. Gao, the CEO has 1.2% of the shares allocated to their name.

我們注意到,對沖基金沒有對瀋陽興奇藥業有限公司進行有意義的投資。劉繼東目前是最大股東,持有29%的已發行股份。全國社會保障基金理事會和Fullgoal基金管理公司分別佔已發行股份的4.8%和3.4%Ltd. 是第二和第三大股東。此外,我們發現,首席執行官高英擁有1.2%的股份分配給他們。

After doing some more digging, we found that the top 14 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

經過進一步的挖掘,我們發現排名前14位的公司合併所有權爲51%,這表明沒有一個股東對公司擁有重要的控制權。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。

Insider Ownership Of Shenyang Xingqi PharmaceuticalLtd

瀋陽興奇藥業有限公司的內幕所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層對董事會負責,後者應代表股東的利益。值得注意的是,有時高層管理人員自己也是董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。

Our information suggests that insiders maintain a significant holding in Shenyang Xingqi Pharmaceutical Co.,Ltd.. It is very interesting to see that insiders have a meaningful CN¥5.6b stake in this CN¥18b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

我們的信息表明,內部人士仍持有瀋陽興奇藥業有限公司的大量股份。,有限公司。看到內部人士在這項180億元人民幣的業務中擁有56億元人民幣的大量股份,這非常有趣。很高興看到這樣的投資水平。你可以在這裏查看這些內部人士最近是否在買入。

General Public Ownership

一般公有制

With a 44% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shenyang Xingqi PharmaceuticalLtd. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

瀋陽興齊藥業有限公司擁有44%的所有權,公衆對瀋陽興奇藥業有限公司有一定程度的影響力,主要由個人投資者組成。儘管這個群體不一定能做主,但它肯定會對公司的運作方式產生真正的影響。

Next Steps:

後續步驟:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Shenyang Xingqi PharmaceuticalLtd (including 1 which is significant) .

儘管值得考慮擁有一家公司的不同群體,但還有其他因素更爲重要。爲此,你應該了解我們在瀋陽興奇製藥有限公司發現的兩個警告信號(包括一個重要的警告)。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論